Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes with liposomal daunorubicin/cytarabine – a single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRafeh SafdarCBCole Blanford

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows relapse rates in acute myeloid leukemia patients treated with CPX-351, indicating ongoing treatment challenges.

Key Points

  • Nineteen patients achieved complete remission or incomplete recovery, showing a critical yet modest outcome.
  • The median overall survival for patients was 9.2 months, highlighting significant treatment limitations in this population.
  • Cox proportional hazards modeling indicated that achieving remission was associated with better overall survival outcomes.
  • Findings stress the necessity for enhanced strategies to manage relapse rates in acute myeloid leukemia patients.

Cite This Study

Safdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d325https://doi.org/10.1182/blood-2025-6973
View Full Paper
Ask AI
Bookmark
Share